Seagate Technology Holdings plc (STX)

Oncternal Therapeutics Stock Forecast

Stock Price Forecast

The 18 analysts that cover Oncternal Therapeutics stock have a consensus rating of "Buy" and an average price target of $146.61, which forecasts a -5.78% decrease in the stock price over the next year. The lowest target is $80 and the highest is $200.

Price Target: $146.61 (-5.78%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$80	$146.61	$155	$200
Change	-48.59%	-5.78%	-0.39%	+28.53%

Analyst Ratings

The average analyst rating for Oncternal Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	5	6	6	6	6	5
Buy	7	7	7	7	7	7
Hold	8	8	8	8	8	5
Sell	1	0	0	0	0	1
Strong Sell	0	0	0	0	0	0
Total	21	21	21	21	21	18

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Erik Woodring Morgan Stanley	Morgan Stanley	Buy Maintains $167 → $168	Buy	Maintains	$167 → $168	+7.97%	Jul 30, 2025
Tristan Gerra Baird	Baird	Buy Maintains $120 → $188	Buy	Maintains	$120 → $188	+20.82%	Jul 30, 2025
Mark Miller Benchmark	Benchmark	Strong Buy Maintains $128 → $165	Strong Buy	Maintains	$128 → $165	+6.04%	Jul 30, 2025
Tom O'Malley Barclays	Barclays	Hold Maintains $90 → $125	Hold	Maintains	$90 → $125	-19.67%	Jul 30, 2025
Mehdi Hosseini Susquehanna	Susquehanna	Sell Maintains $68 → $80	Sell	Maintains	$68 → $80	-48.59%	Jul 30, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

10.42B

Increased by 14.50%

from 9.10B

Revenue Next Year

11.06B

Increased by 6.17%

from 10.42B

EPS This Year

9.84

Increased by 45.36%

from 6.77

EPS Next Year

11.73

Increased by 19.24%

from 9.84

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Jul 2, 2021	Jul 1, 2022	Jun 30, 2023	Jun 28, 2024	Jun 27, 2025	Jun 30, 2026	Jun 30, 2027	Jun 30, 2028
Revenue	10.68B	11.66B	7.38B	6.55B	9.10B	10.42B	11.06B	12.09B
Revenue Growth	1.64%	9.18%	-36.68%	-11.28%	38.86%	14.50%	6.17%	9.30%
EPS	5.36	7.36	-2.56	1.58	6.77	9.84	11.73	12.49
EPS Growth	41.43%	37.31%	-	-	328.48%	45.36%	19.24%	6.47%
Forward PE	-	-	-	-	-	15.81	13.26	12.45
No. Analysts	-	-	-	-	-	25	15	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029
High	11.5B	12.6B	13.7B
Avg	10.4B	11.1B	12.1B
Low	9.0B	9.3B	10.7B

Revenue Growth

Revenue Growth	2026	2027	2028	2029
High	26.2%	21.2%	24.0%
Avg	14.5%	6.2%	9.3%
Low	-1.2%	-10.3%	-3.7%

EPS Forecast

EPS	2026	2027	2028	2029
High	11.59	14.81	17.33
Avg	9.84	11.73	12.49
Low	6.35	8.07	8.08

EPS Growth

EPS Growth	2026	2027	2028	2029
High	71.2%	50.4%	47.6%
Avg	45.4%	19.2%	6.5%
Low	-6.2%	-18.0%	-31.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.